Prehypertension: A warning sign of future cardiovascular risk

International Journal of Preventive Medicine

Volumn 5, Issue SUPPL, 2014, Pages

  Assadi, Farahnak ^a,b  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cardiovascular disease; Children and adolescents; Essential hypertension; Pre hypertension; Prevention

Indexed keywords

CANDESARTAN; PLACEBO; RAMIPRIL; URIC ACID;

BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR RISK; DIET; ESSENTIAL HYPERTENSION; HIGH RISK POPULATION; HUMAN; HYPERTENSION; HYPERURICEMIA; NONHUMAN; OBESITY; PATHOGENESIS; PREDICTION; PREHYPERTENSION; PREVALENCE; PRIMARY PREVENTION; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; STRESS MANAGEMENT;

EID: 84897911825     PISSN: 20087802     EISSN: 20088213     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Redwine KM, Daniels SR. Prehypertension in adolescents: Risk and progression. J Clin Hypertens (Greenwich) 2012;14:360-4.
2. McNiece KL, Poffenbarger TS, Turner JL, Franco KD, Sorof JM, Portman RJ. Prevalence of hypertension and pre-hypertension among adolescents. J Pediatr 2007;150:640-4, 644.e1.
3. Redwine KM, Falkner B. Progression of prehypertension to hypertension in adolescents. Curr Hypertens Rep 2012;14:619-25.
4. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 2004;114:555-76.
5. Hansen ML, Gunn PW, Kaelber DC. Underdiagnosis of hypertension in children and adolescents. JAMA 2007;298:874-9.
6. Sorof J, Daniels S. Obesity hypertension in children: A problem of epidemic proportions. Hypertension 2002;40:441-7.
7. Falkner B, Gidding SS, Ramirez-Garnica G, Wiltrout SA, West D, Rappaport EB. The relationship of body mass index and blood pressure in primary care pediatric patients. J Pediatr 2006;148:195-200.
8. Muntner P, He J, Cutler JA, Wildman RP, Whelton PK. Trends in blood pressure among children and adolescents. JAMA 2004;291:2107-13.
9. Din-Dzietham R, Liu Y, Bielo MV, Shamsa F. High blood pressure trends in children and adolescents in national surveys, 1963 to 2002. Circulation 2007;116:1488-96.
10. Vasan RS, Larson MG, Leip EP, Evans JC, O'Donnell CJ, Kannel WB, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001;345:1291-7.
11. Qureshi AI, Suri MF, Kirmani JF, Divani AA, Mohammad Y. Is prehypertension a risk factor for cardiovascular diseases? Stroke 2005;36:1859-63.
12. Hsia J, Margolis KL, Eaton CB, Wenger NK, Allison M, Wu L, et al. Prehypertension and cardiovascular disease risk in the Women's Health Initiative. Circulation 2007;115:855-60.
13. Assadi F. Strategies to reduce the incidence of chronic kidney disease in children: Time for action. J Nephrol 2013;26:41-7.
14. Assadi F. Relation of left ventricular hypertrophy to microalbuminuria and C-reactive protein in children and adolescents with essential hypertension. Pediatr Cardiol 2008;29:580-4.
15. Gidding SS. Measuring children〉s blood pressure matters. Circulation 2008;117:3163-4.
16. Bao W, Threefoot SA, Srinivasan SR, Berenson GS. Essential hypertension predicted by tracking of elevated blood pressure from childhood to adulthood: The Bogalusa Heart Study. Am J Hypertens 1995;8:657-65.
17. Fuentes RM, Notkola IL, Shemeikka S, Tuomilehto J, Nissinen A. Tracking of systolic blood pressure during childhood: A 15-year follow-up population-based family study in eastern Finland. J Hypertens 2002;20:195-202.
18. Falkner B, Gidding SS, Portman R, Rosner B. Blood pressure variability and classification of prehypertension and hypertension in adolescence. Pediatrics 2008;122:238-42.
19. Franklin SS, Pio JR, Wong ND, Larson MG, Leip EP, Vasan RS, et al. Predictors of new-onset diastolic and systolic hypertension: The Framingham Heart Study. Circulation 2005;111:1121-7.
20. Toprak A, Wang H, Chen W, Paul T, Ruan L, Srinivasan S, et al. Prehypertension and black-white contrasts in cardiovascular risk in young adults: Bogalusa Heart Study. J Hypertens 2009;27:243-50.
21. Julius S, Nesbitt S, Egan B, Kaciroti N, Schork MA, Grozinski M, et al. Trial of preventing hypertension: Design and 2-year progress report. Hypertension 2004;44:146-51.
22. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med 2008;359:1811-21.
23. Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 2001;38:1101-6.
24. Mazzali M, Kanellis J, Han L, Feng L, Xia YY, Chen Q, et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol 2002;282:F991-7.
25. Soletsky B, Feig DI. Uric acid reduction rectifies prehypertension in obese adolescents. Hypertension 2012;60:1148-56.
26. Feig DI. Hyperuricemia and hypertension. Adv Chronic Kidney Dis 2012;19:377-85.
27. Assadi F. Coadministration of allopurinol enhances blood pressure lowering effect of enalapril in children with hyperuricemic essential hypertension. J Nephrol 2014. DOI 10.1007/s40620-013-0009-0.
28. Julius S, Nesbitt SD, Egan BM, Weber MA, Michelson EL, Kaciroti N, et al. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 2006;354:1685-97.
29. Assadi F. The growing epidemic of hypertension among children and adolescents: A challenging road ahead. Pediatr Cardiol 2012;33:1013-20.
30. Flynn JT, Falkner BE. Obesity hypertension in adolescents: Epidemiology, evaluation, and management. J Clin Hypertens (Greenwich) 2011;13:323-31.
31. King DE, Egan BM, Mainous AG 3rd, Geesey ME. Elevation of C-reactive protein in people with prehypertension. J Clin Hypertens (Greenwich) 2004;6:562-8.
32. Assadi F. Effect of microalbuminuria lowering on regression of left ventricular hypertrophy in children and adolescents with essential hypertension. Pediatr Cardiol 2007;28:27-33.32.
33. Chrysohoou C, Pitsavos C, Panagiotakos DB, Skoumas J, Stefanadis C. Association between prehypertension status and infl ammatory markers related to atherosclerotic disease: The ATTICA Study. Am J Hypertens 2004;17:568-73.
34. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-13.
35. Parikh NI, Pencina MJ, Wang TJ, Benjamin EJ, Lanier KJ, Levy D, et al. A risk score for predicting near-term incidence of hypertension: The Framingham Heart Study. Ann Intern Med 2008;148:102-10.
36. Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med 1997;336:1117-24.
37. Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med 2001;344:3-10.
38. Player MS, King DE, Mainous AG 3rd, Geesey ME. Psychosocial factors and progression from prehypertension to hypertension or coronary heart disease. Ann Fam Med 2007;5:403-11.
39. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206-52.
40. Appel LJ, Champagne CM, Harsha DW, Cooper LS, Obarzanek E, Elmer PJ, et al. Effects of comprehensive lifestyle modification on blood pressure control: Main results of the PREMIER clinical trial. JAMA 2003;289:2083-93.
41. Flack JM, Sica DA, Bakris G, Brown AL, Ferdinand KC, Grimm RH Jr, et al. Management of high blood pressure in Blacks: An update of the International Society on Hypertension in Blacks consensus statement. Hypertension 2010;56:780-80.
42. Lüders S, Schrader J, Berger J, Unger T, Zidek W, Böhm M, et al. The PHARAO study: Prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure: A prospective, randomized, controlled prevention trial of the German Hypertension League. J Hypertens 2008;26:1487-96.
43. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) fi nal report. Circulation 2002;106:3143-421.
44. Systolic Blood Pressure Intervention Trial (SPRINT). Clinical trials.gov identifi er: Clinical trial identifi er NCT01206062. Available from: http://clinicaltrials.gov. [Last accessed on 2013 May 17].